



Notice of Investment Agreement with Niremia Collective

OSAKA, Japan, January 25, 2024 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that we have concluded investment agreement with Niremia Collective, a venture capital firm specializing in Well-being Technology-focused funds (Headquarters: California, USA; Representative: Naoko Okumoto, Co-founder and Managing Partner; hereafter "Niremia").

Niremia is a venture capital firm that operates funds specializing in Well-being Technology. It has the world's largest global platform that connects investors and resources (talent, funding, etc.) in the Well-being Technology industry with founders of emerging companies.

Shionogi's investment through this Agreement is expected to be strategically utilized by Niremia to support and nurture emerging companies in the Well-being Technology field, thereby promoting research and development efforts of emerging technology companies and accelerating the creation of innovative solutions to address new needs.

Furthermore, through our strategic partnership with Niremia, Shionogi aims to enhance its understanding of business trends related to Well-being Technology and establish a network with emerging companies. We will also focus on talent development through the utilization of an internship program with Niremia. It is anticipated that Shionogi will receive revenue distribution based on this Agreement.

Under the SHIONOGI Group Vision of " Building Innovation Platforms to Shape the Future of Healthcare", Shionogi is committed to providing total care through healthcare services that go beyond simply providing medications, addressing the issues faced by patients and society comprehensively. By leveraging the external network through this Agreement, we will continue to promote research and development in order to develop and provide innovative pharmaceutical products and medical services to meet unmet needs of patients worldwide.

【About Well-being Technology】

The term "well-being" refers to a state of happiness and fulfillment and is also used in the context of health as a concept and definition. In recent years, the achievement of a safe, healthy, and well-being society from an SDGs perspective has gained international attention as a global commitment. There is increasing attention on the potential contribution of advanced technology to solving various social challenges and achieving a well-being society.

【About Niremia Collective】

Niremia Collective is a venture capital firm based in California that operates a specialized fund focused on well-being technology. Niremia Collective, founded by business development and investment experts in Silicon Valley and the Asia-Pacific region, Naoko Okumoto and Nichol Bradford, founder of Transformative Technology (abbreviated as Transtech), the world's largest and most prestigious well-being technology ecosystem.

Transtech currently has over 9,000 members in 72 countries, including startups, investors, universities, research institutions, and companies. They are dedicated to investing in innovative technology companies that promote individual happiness. With a focus on innovative solutions, Niremia Collective collaborates with visionary entrepreneurs to drive positive changes in the rapidly evolving well-being technology landscape.

Company URL: <https://www.niremia.vc/>

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form : <https://www.shionogi.com/global/en/contact.html>